Exercise-Induced Pulmonary Hypertension: What Is New?

Exercise-induced pulmonary hypertension (EIPH) represents an abnormal pulmonary vascular response to increased blood flow during exercise, best characterized by a disproportionate rise in pulmonary arterial pressure relative to cardiac output. The shift from fixed pressure thresholds to flow-adjusted metrics, particularly the mPAP–cardiac output slope, reflects a more physiologically sound approach and is now incorporated in the 2022 guidelines of the European Society of Cardiology/European Respiratory Society as well as the World Symposium on PH. EIPH is a hemodynamic phenotype, not a standalone disease. Accumulating evidence demonstrates that EIPH has important diagnostic and prognostic implications. It is associated with reduced exercise capacity, increased risk of adverse cardiovascular outcomes, and reduced survival, even in patients with normal resting hemodynamics. Exercise hemodynamic abnormalities may also identify early or latent pulmonary vascular disease and early left heart dysfunction, particularly in at-risk populations such as systemic sclerosis, HFpEF, and genetic predisposition. In this review, we provide the current definition of EIPH as well as an overview of the prognostic implications and management of exercise-induced PH in cardiac and pulmonary diseases.